INTRODUCTION AND OBJECTIVES: Patient and disease characteristics influence ureteric stricture management with DJ stents, metallic stents, endoscopic, or reconstructive surgery. Memokaths are an option with reported 90-100% patency and 14-30% complication rates, but the published literature is limited by small sample size and short follow-up duration up to 22 months. Objective: To independently analyse 5-year Memokath stent outcomes, identifying variables associated with good outcomes to update clinical guidelines.
INTRODUCTION AND OBJECTIVES: Patient and disease characteristics influence ureteric stricture management with DJ stents, metallic stents, endoscopic, or reconstructive surgery. Memokaths are an option with reported 90-100% patency and 14-30% complication rates, but the published literature is limited by small sample size and short follow-up duration up to 22 months. Objective: To independently analyse 5-year Memokath stent outcomes, identifying variables associated with good outcomes to update clinical guidelines.
METHODS: Management of obstructed ureteric stricture patients with Memokath stents was reviewed independently using electronic patient records. Outcomes included time to first complication, complications' incidence and severity. Multiple linear regression was performed identifying variables linked with particular outcomes.
RESULTS: 100 patients aged 23-87 years (mean 57) received Memokath stents for ureteric obstruction, 59% for malignant strictures, with 20% bilateral. Only 25 patients had no complications: either alive with, or dying of their primary malignancy with their original Memokath. Median time to complication in the remaining 75 patients was 12.5 months with Memokaths lasting longer in patients with malignancy (p¼0.02). Multiple linear regression analyses showed that increased eGFR (p¼0.005) and age (p¼0.0001) independently significantly predicted greater Memokath lifespan, while co-morbidities, stricture length and location, and underlying pathology, did not. 5 year outcomes: 25 patients had a Memokath in situ: 14 still alive with the original. 22 had other stents, while 12 required major surgery. 66% of patients with most severe complications (need for major surgery or dialysis) were in the benign group.
CONCLUSIONS: Memokaths are a reasonable option for patients with malignant ureteric obstruction and life expectancy up to 1 year. Age and eGFR greater than 45 predicted longer Memokath duration. Patient and stricture variables other than aetiology did not affect Memokath durability, but should be considered for delivery of the most appropriate patient-centred individualised care. 5 year complication rates were significantly higher than previously reported (75 vs 25%). Updated practice guidelines would aid future patient selection and counselling, as well as encouraging protocolled follow-up and patient reported outcomes assessment, when considering metallic stent drainage for ureteric obstruction. METHODS: This randomized controlled trial included 135 patients who were treated with BMGU between 2014 and 2015. The buccal mucosa graft was harvested from the inner cheek. Following computer-based randomization, 63 and 72 patients received C and NC of the donor site. Preoperatively, at postoperative day (POD) one, 5, 21 as well as 3 and 6 months postoperatively, patients completed standardized questionnaires. The intensity of oral pain and of the perineogenital region, respectively, was assessed with a numeric rating scale (NRS). The quality of oral pain was evaluated using the Short-Form McGill Pain Questionnaire (SF-MPQ), consisting of a sensory and affective pain subscale. The co-primary endpoints were intensity and quality of oral pain. Secondary endpoints included oral morbidity as well as intensity of pain of the perineogenital region. Generalized linear mixed models evaluated the effect of C versus NC on intensity and quality of oral pain, oral morbidity as well as intensity of pain of the perineogenital region.
RESULTS: Oral pain intensity mean scores on the NRS were 0.15 (standard deviation (SD): 0.531; range: 0-3), 3.16 (SD: 2.10; range: 0-10), 2.89 (SD: 2.16; range: 0-9), 1.30 (SD: 1.72; range: 0-8), 1.00 (SD: 1.42; range: 0-6) and 0.77 (SD: 1.33; range: 0-6), respectively, at baseline, POD one, 5, 21 as well as 3 and 6 months. The most frequent sensory dimension of pain was 0 tender 0 . The most common affective dimension of pain was 0 tiring-exhausting 0 on POD one, 5 and 3 months. On POD 21 and 6 months, the most frequent affective pain was 0 fearful 0 . Oral morbidity and complications included pain, bleeding, swelling, numbness, alteration of salivation and taste, as well as impairment of mouth opening, smiling, diet and speech. C versus NC of the donor site had no effect on intensity and quality of oral pain as well as morbidity and complications. Time from BMGU and length of buccal mucosa graft had significant effects on intensity and quality of oral pain (p-values<0.042). Mean NRS cores of the pain intensity of the perineogenital region were 0.86 (SD: 1.74; range: 0-8), 3.94 (SD: 2.24; range: 0-10), 2.70 (SD: 2.08; range: 0-8), 1.81 (SD: 1.63; range: 0-8), 1.37 (SD: 1.71; range: 0-8) and 1.18 (SD: 1.76; range: 0-7), respectively, at baseline, POD one, 5, 21 as well as 3 and 6 months. C versus NC had no effect on intensity of pain of the perineogenital region. Time from BMGU, length of the buccal mucosa graft and perioperative analgesic medication had significant effects on the intensity of pain of the perineogenital region (p-values<0.035).
CONCLUSIONS: In conclusion, C versus NC of the donor site has no effect on intensity and quality of oral pain, morbidity and complications. Both, C and NC of the buccal mucosa harvest site, are feasible and safe procedures.
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PD60-11 POPULATION-BASED MANAGEMENT OF MALE URETHRAL STRICTURE DISEASE
Robert Goldfarb*, Steven Brandes, New York, NY; Peter Kirk, Tudor Borza, Yongmei Qin, Ted Skolarus, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: Male urethral stricture disease is a common condition with significant quality of life and economic implications. While endoscopic treatment with incision or dilation is the most common treatment approach, the AUA guidelines (www.auanet.org/guidelines) recommend urethroplasty based on increased long-term success rates. However, the extent to which this procedure is performed relative to endoscopic treatment in real-world practice in the USA is unknown. Thus, we conducted a populationbased study of patients treated for urethral stricture disease to examine management patterns and opportunities for improvement.
METHODS: We identified male patients who underwent procedures for urethral stricture disease between 2001 and June 2015 based on ICD-9 codes and administrative claims from a large, national US health insurer (Clinformatics TM Data Mart Database, Optum Insight, Eden Prairie, MN). We assessed utilization and standardized cost of endoscopic treatments (urethrotomy and dilation) and urethroplasty. We examined patient factors associated with endoscopic treatment versus urethroplasty using multivariable logistic regression.
e1186
THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 RESULTS: We identified a total of 75,522 patients treated for male urethral stricture disease with 125,498 total procedures. This is the largest reported cohort of urethral stricture procedures in the literature. The majority of patients were treated with endoscopic surgery (98.8%), with only 1,515 patients undergoing urethroplasty. After adjustment, younger age (adjusted odds ratio (aOR), age 40 vs. age 60 years, 8.2; 95% CI, 7.2-9.4) and higher annual income (aOR, income $40K vs. $100,00K, 0.7; 95% CI, 0.5-0.9) were each associated with receipt of urethroplasty. Total standardized costs for endoscopic treatment was $115,724,899 compared to $3,678,066 for urethroplasty.
CONCLUSIONS: Our population-based study of insured patients demonstrated very low use of urethroplasty in real-world practice, despite recommendations for use and superior success rates. Income disparities in urethroplasty utilization is concerning and may indicate health access disparity. Strategies to increase the use of high value surgery for patients with urethral stricture disease include increasing referrals to reconstructive urologists, and knowledge and technique transfer to community urologists interested in providing this service rather than repeated, low-value endoscopic treatment.
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PD60-12 GERIATRIC URETHROPLASTY: LESSONS LEARNED FROM URETHRAL RECONSTRUCTION IN ELDERLY MEN
Boyd Viers*, Travis Pagliara, Charles Rew, Dallas, TX; Lauren Folgosa-Cooley, Richmond, VA; Christine Shiang, Jeremy Scott, Allen Morey, Dallas, TX INTRODUCTION AND OBJECTIVES: While urethroplasty remains safe and effective in younger populations, little data exists evaluating outcomes of urethroplasty in elderly men. We report treatment outcomes, complications, and stricture characteristics among men having urethral reconstruction who were 70 years of age.
METHODS: A retrospective review of over 1000 urethroplasty cases by a single surgeon from 2007-2014 was performed to identify elderly men 70 years undergoing urethral reconstruction. Men were stratified by age and differences were assessed including stricture characteristics, postoperative complications, and surgical outcomes. Mutivariable logistic regression models evaluated the association between age and surgical outcome. Men with a history of hypospadias were excluded. RESULTS: Among 514 men having urethroplasty for which complete data was available, 85 (17%) were 70 years. Elderly men were more likely to have a history of radiation therapy (63% vs 5%, p<0.0001) and experience treatment failure (30% vs 12%, p¼0.001) during follow up (mean 20 months). Accordingly, the 24-month stricture recurrence-free survival was 61% vs 78% (p¼0.03). In men 70, the success rates of excision and primary anastomosis (EPA), substitution urethroplasty, and urethrostomy were 75%, 67%, and 80%. While stricture length, location, and prior endoscopic treatments were similar between cohorts, elderly men were more likely to have obliterative strictures (44% vs 28%), a shorter duration between diagnosis and treatment (median 46 vs 61 months), and undergo EPA (80% vs 66%). Following surgery there was no difference in overall <90 day complications (22% vs 18%); however elderly men were more likely to have a Clavien 3 or greater complication (13% vs 5%; p¼0.005). Among treatment failures, men 70 failed earlier (8 vs 18 months; p¼0.04) and were more likely to fail on subsequent intervention (55% vs 30%; p¼0.05). On multivariable analysis, radiation (OR 2.91, 95% CI 1.36-6.24; p¼0.006) and increasing age (OR 1.03, 95%CI 1.01-1.05; p¼0.006) were independently associated with risk of treatment failure.
CONCLUSIONS: While advanced age is independently associated with urethroplasty failure, urethroplasty is a safe and effective treatment option for aging men with urethral stricture disease. METHODS: Overall, 60 patients were consecutively and prospectively enrolled and underwent 18F-FACBC-PET/CT. Inclusion criteria were: intermediate and high-risk biopsy-proven PCa according to D'Amico risk group classification; standard staging workup (including 11C-Choline-PET/CT); absence of previous or ongoing androgen deprivation therapy; eligible for PLND in course of RP. Any nodal uptake greater than surrounding background was interpreted with a visual 5-point-scale (confidence of disease): 1-2 probably negative; 4-5 probably positive; 3 equivocal. Lesions' number, site and size, SUV max and target-to-background-ratio were also recorded. PET/CT results using both tracers were compared, on a perpatient basis analysis, with histopathology from extended PLND (60 patients).
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RESULTS: Main characteristics of the population are shown in Table 1 . Overall, 1342 lymph nodes were retrieved and 32 (2%) LNMs were counted. At final pathologic results, we found 9 and 15 false positive (FP) results with FACBC and Choline, respectively; while 5 false negative (FN) results were found with both tracers. The diagnostic performance of both tracers in detecting LNMs are summarized in Table 2 : sensitivity, specificity and accuracy were 58%, 69% and 67% vs. 58%, 81% and 77% for 11C-Choline PET/CT vs. 18F-fluciclovine PET/CT, respectively. CONCLUSIONS: Conclusion: 18F-fluciclovine demonstrated suboptimal sensitivity, equal to Choline, suggesting that neither tracer is ideal for PCa nodal staging. However, our preliminary data show
